ADVERTISEMENT
Israel
Israeli startup by biomedical researcher and entrepreneur Morris Laster using research from ChEM-H Institute scholar at Stanford to will develop and market compounds as nutraceuticals to offer an effective, affordable and side-effect-free solution for weight loss.
Teva enjoyed a favorable tax status for years in its domestic Israel. However, after the firm battled in court against challenges to its historic tax payments, Teva has now agreed a three-quarters-of-a-billion dollar settlement agreement with the Israel Tax Authority.
J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.
Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.
In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.
As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
FDA continues to see in-person inspections as more efficient and more effective than ‘virtual’ alternatives, which means almost all domestic inspections will be handled by traditional site visits.
US FDA continues to see in-person inspections as more efficient and more effective than ‘virtual’ alternatives. And that means that almost all domestic inspections will be handled by traditional site visits.
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.